A proprietary delivery system designed for the lower gastrointestinal tract, featuring a dual mode of action with an immediate release layer and an extended-release therapeutic layer.

Treatments targeting metabolic syndrome and motility disorders using chenodeoxycholate (CDC) to activate GLP-1 and other incretins, and to improve fluid influx and peristalsis in the colon.